Autism Spectrum Disorder: Classification, diagnosis and therapy

Pharmacology and Therapeutics

Volumn 190, Issue , 2018, Pages 91-104

  Sharma, Samata R ^a   Gonda, Xenia ^b   Tarazi, Frank I ^c  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b SEMMELWEIS UNIVERSITY   (Hungary)

^c MCLEAN HOSPITAL   (United States)

Author keywords

Asperger's syndrome; Autism; Cognitive behavioral therapy; Comorbid disorders; Music therapy; Pervasive developmental disorder

Indexed keywords

ARIPIPRAZOLE; CITALOPRAM; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; GUANFACINE; NUTRITION SUPPLEMENT; OLANZAPINE; OMEGA 3 FATTY ACID; PSYCHOSTIMULANT AGENT; QUETIAPINE; RISPERIDONE; SERTRALINE; ZIPRASIDONE; PSYCHOTROPIC AGENT;

ALTERNATIVE MEDICINE; ANXIETY DISORDER; ASPERGER SYNDROME DIAGNOSTIC INTERVIEW; ATTENTION DEFICIT DISORDER; AUTISM; AUTISM ASSESSMENT; AUTISM DIAGNOSTIC INTERVIEW REVISED; AUTISM SPECTRUM DISORDER DIAGNOSIS SCALE FOR INTELLECTUALLY DISABLED ADULT; AUTISM SPECTRUM DISORDER OBSERVATION FOR CHILDREN; BEHAVIOR THERAPY; BIPOLAR DISORDER; CHILDHOOD AUTISM RATING SCALE; CHILDHOOD ONSET SCHIZOPHRENIA; COGNITIVE BEHAVIORAL THERAPY; DEPRESSION; DIAGNOSTIC INTERVIEW FOR SOCIAL AND COMMUNICATION DISORDER; DIET SUPPLEMENTATION; DIET THERAPY; DISEASE CLASSIFICATION; GILLES DE LA TOURETTE SYNDROME; HERBAL MEDICINE; HUMAN; MUSIC THERAPY; NEUROBIOLOGY; NEUROMODULATION; NEUROPATHOLOGY; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; REVIEW; RISK FACTOR; SCHIZOPHRENIA; SOCIAL BEHAVIORAL THERAPY; TIC; CLASSIFICATION; DIETARY SUPPLEMENT; DRUG DEVELOPMENT; PREVALENCE; PROCEDURES; PSYCHOLOGICAL RATING SCALE;

AUTISM SPECTRUM DISORDER; BEHAVIOR THERAPY; DIETARY SUPPLEMENTS; DRUG DEVELOPMENT; HUMANS; MUSIC THERAPY; PREVALENCE; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTROPIC DRUGS; RISK FACTORS;

EID: 85047614616     PISSN: 01637258     EISSN: 1879016X     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2018.05.007     Document Type: Review

References (193)

1. Alaghband-Rad, J., McKenna, K., Gordon, C.T., Albus, K.E., Hamburger, S.D., Rumsey, J.M., Rapoport, J.L., Childhood-onset schizophrenia: The severity of premorbid course. Journal of the American Academy of Child and Adolescent Psychiatry 34 (1995), 1273–1283.
2. Altenmüller, E., Schlaug, G., Apollo's gift: New aspects of neurologic music therapy. Progress in Brain Research 217 (2015), 237–252.
3. Alvares, G.A., Quintana, D.S., Whitehouse, A.J., Beyond the hype and hope: Critical considerations for intranasal oxytocin research in autism spectrum disorder. Autism Research 10 (2017), 25–41.
4. Aman, M.G., Farmer, C.A., Hollway, J., Arnold, L.E., Treatment of inattention, overactivity, and impulsiveness in autism spectrum disorders. Child and Adolescent Psychiatric Clinics of North America 17:4 (2008), 713–738.
5. American Psychiatric Association, Diagnostic and statistical manual of mental disorders: DSM-IV-TR. 2000, American Psychiatric Association, Washington, DC.
6. Andrade, S.E., Raebel, M.A., Brown, J., Lane, K., Livingston, J., Boudreau, D., Platt, R., Use of antidepressant medications during pregnancy: A multisite study. American Journal of Obstetrics and Gynecology, 198, 2008 (194 e1-e5).
7. Aoki, Y., Watanabe, T., Abe, O., Kuwabara, H., Yahata, N., Takano, Y., Yamasue, H., Oxytocin's neurochemical effects in the medial prefrontal cortex underlie recovery of task-specific brain activity in autism: A randomized controlled trial. Molecular Psychiatry 20 (2015), 447–453.
8. Asperger, H., Die “Autistischen Psychopathen” im Kindesalter [autistic psychopaths in childhood]. Archiv für Psychiatrie und Nervenkrankheiten (in German) 117 (1944), 76–136.
9. Autism Speaks, Autism Speaks Announces Results Reported for the Study of Fluoxetine in Autism (SOFIA), First Industry-Sponsored Trial for the Autism Clinical Trials Network (ACTN). https://www.autismspeaks.org/about-us/press-releases/autism-speaks-announces-results-reported-study-fluoxetine-autism-sofia, 2009, Feb 18.
10. Bahmani, M., Sarrafchi, A., Shirzad, H., Rafieian-Kopaei, M., Autism: Pathophysiology and promising herbal remedies. Current Pharmaceutical Design 22 (2016), 277–285.
11. Baldessarini, R.J., Tarazi, F.I., Pharmacotherapy of psychosis and mania. Brunton, L.L., Lazo, J.S., Parker, K.L., (eds.) Goodman and Gilman's the pharmacological basis of therapeutics, 2005, McGraw-Hill, New York, NY, 461–500.
12. Bang, M., Lee, S.H., Cho, S.H., Yu, S.A., Kim, K., Lu, H.Y., Min, S.Y., Herbal medicine treatment for children with autism spectrum disorder: A systematic review. Evidence-based Complementary and Alternative Medicine, 8614680, 2017.
13. Baum, S., Stevenson, R., Wallace, M., Behavioral, perceptual, and neural alterations in sensory and multisensory function in autism spectrum disorder. Progress in Neurobiology 134 (2015), 140–160.
14. Bauman, M.L., Medical comorbidities in autism: Challenges to diagnosis and treatment. Neurotherapeutics 7:3 (2010), 320–327.
15. Blankenship, K., Erickson, C.A., Stigler, K.A., Posey, D.J., McDougle, C.J., Aripiprazole for irritability associated with autistic disorder in children and adolescents aged 6–17 years. Pediatric Health 4:4 (2010, Sep 29), 375–381.
16. Bolton, P., Macdonald, H., Pickles, A., Rios, P., Goode, S., Crowson, M., Rutter, M., A case-control family history study of autism. Journal of Child Psychology and Psychiatry 35:5 (1994), 877–900.
17. Bonnel, A., Mottron, L., Peretz, I., Trudel, M., Gallun, E., Bonnel, A.M., Enhanced pitch sensitivity in individuals with autism: A signal detection analysis. Journal of Cognitive Neuroscience 15:2 (2003), 226–235.
18. Boukhris, T., Sheehy, O., Mottron, L., Bérard, A., Antidepressant use during pregnancy and the risk of autism spectrum disorder in children. JAMA Pediatrics, 170(2), 2016 (117-112).
19. Brondino, N., Fusar-Poli, L., Rocchetti, M., Provenzani, U., Barale, F., Politi, P., Complementary and alternative therapies for autism spectrum disorder. Evidence-based Complementary and Alternative Medicine, 2015, 2015, 258589.
20. Buchsbaum, M.S., Hollander, E., Haznedar, M.M., Tang, C., Spiegel-Cohen, J., Wei, T.C., Mosovich, S., Effect of fluoxetine on regional cerebral metabolism in autistic spectrum disorders: A pilot study. International Journal of Neuropsychopharmacology 4:2 (2001), 119–125.
21. Burd, L., Li, Q., Kerbeshian, J., Klug, M.G., Freeman, R.D., Tourette syndrome and comorbid autism spectrum disorders. Journal of Child Neurology 24 (2009), 170–175.
22. Cai, Q., Feng, L., Yap, K.Z., Systematic review and meta-analysis of reported adverse events of long-term intranasal oxytocin treatment for autism spectrum disorder. Psychiatry and Clinical Neurosciences, 2018 (in press).
23. Canitano, R., Vivanti, G., Tics and Tourette syndrome in autism spectrum disorders. Autism 11:1 (2007), 19–28.
24. Cavanna, A.E., Termine, C., Tourette syndrome. Advances in Experimental Medicine and Biology 724 (2012), 375–383.
25. Cerliani, L., Mennes, M., Thomas, R.M., Di Martino, A., Thioux, M., Keysers, C., Increased functional connectivity between subcortical and cortical resting-state networks in autism spectrum disorder. JAMA Psychiatry 72:8 (2015), 767–777.
26. Chaidez, V., Hansen, R.L., Hertz-Picciotto, I., Gastrointestinal problems in children with autism, developmental delays or typical development. Journal of Autism and Developmental Disorders 44 (2014), 1117–1127.
27. Chandrasekhar, T., Challenges in the diagnosis and treatment of depression in autism spectrum disorder across the lifespan. Dialogues in Clinical Neuroscience 17:2 (2015), 219–227.
28. Christensen, D.L., Baio, J., Van Naarden, B.K., Bilder, D., Charles, J., Constantino, J.N., Centers for Disease Control and Prevention, Prevalence and characteristics of autism spectrum disorder among children aged 8 years—Autism and Developmental Disabilities Monitoring Network, 11 Sites, United States, 2012. MMWR Surveillance Summaries 65:3 (2016), 1–23.
29. Cohen, H., Amerine-Dickens, M., Smith, T., Early intensive behavioral treatment: Replication of the UCLA model in a community setting. Journal of Developmental and Behavioral Pediatrics 27 (2006), S145–S155.
30. Cohen, S.A., Fitzgerald, B.J., Khan, S.R., Khan, A., The effect of a switch to ziprasidone in an adult population with autistic disorder: Chart review of naturalistic, open-label treatment. The Journal of Clinical Psychiatry 65:1 (2004), 110–113.
31. Corson, A.H., Barkenbus, J.E., Posey, D.J., Stigler, K.A., McDougle, C.J., A retrospective analysis of quetiapine in the treatment of pervasive developmental disorders. The Journal of Clinical Psychiatry 65 (2004), 1531–1536.
32. Couturier, J.L., Nicholson, R., A retrospective assessment of citalopram in children and adolescents with pervasive developmental disorders. Journal of Child and Adolescent Psychopharmacology 12 (2002), 243–248.
33. Croen, L.A., Grether, J.K., Yoshida, C.K., Odouli, R., Hendrick, V., Antidepressant use during pregnancy and childhood autism spectrum disorders. Archives of General Psychiatry 68 (2011), 1104–1112.
34. Dadds, M.R., MacDonald, E., Cauchi, A., Williams, K., Levy, F., Brennan, J., Nasal oxytocin for social deficits in childhood autism: A randomized controlled trial. Journal of Autism and Developmental Disorders 44 (2014), 521–531.
35. Danial, J.T., Wood, J.J., Cognitive behavioral therapy for children with autism: Review and considerations for future research. Journal of Developmental and Behavioral Pediatrics 34 (2013), 702–715.
36. Dapretto, M., Davies, M.S., Pfeifer, J.H., Scott, A.A., Sigman, M., Bookheimer, S.Y., Iacoboni, M., Understanding emotions in others: Mirror neuron dysfunction in children with autism spectrum disorders. Nature Neuroscience 9:1 (2006), 28–30.
37. Davis, N.O., Kollins, S.H., Treatment for co-occurring attention deficit/hyperactivity disorder and autism spectrum disorder. Neurotherapeutics 9:3 (2012), 518–530.
38. Davis, T.E., Hess, J.A., Moree, B.N., Fodstad, J.C., Dempsey, T., Jenkins, W.S., Anxiety symptoms across the lifespan in people diagnosed with autistic disorder. Research in Autism Spectrum Disorders 5 (2011), 112–118.
39. Dawson, G., Rogers, S., Munson, J., Smith, M., Winter, J., Greenson, J., Varley, J., Randomized, controlled trial of an intervention for toddlers with autism: The Early Start Denver Model. Pediatrics 125 (2010), e17–e23.
40. DePape, A.M., Hall, G.B., Tillmann, B., Trainor, L.J., Auditory processing in high-functioning adolescents with autism spectrum disorder. PLoS One, 7(9), 2012, e44084.
41. DiGuiseppi, C., Hepburn, S., Davis, J.M., Fidler, D.J., Hartway, S., Lee, N.R., Robinson, C., Screening for autism spectrum disorders in children with down syndrome. Journal of Developmental and Behavioral Pediatrics 31 (2010), 181–191.
42. Dohn, A., Garza-Villarreal, E.A., Heaton, P., Vuust, P., Do musicians with perfect pitch have more autism traits than musicians without perfect pitch? An empirical study. PLoS One, 7(5), 2012, e37961.
43. Domes, G., Heinrichs, M., Kumbier, E., Grossmann, A., Hauenstein, K., Herpertz, S.C., Effects of intranasal oxytocin on the neural basis of face processing in autism spectrum disorder. Biological Psychiatry 74 (2013), 164–171.
44. Durkin, M.S., Maenner, M.J., Newschaffer, C.J., Lee, L.C., Cunniff, C.M., Daniels, J.L., Schieve, L.A., Advanced parental age and the risk of autism spectrum disorder. American Journal of Epidemiology 168:11 (2008, Dec 1), 1268–1276.
45. Erickson, C.A., Stigler, K.A., Corkins, M.R., Posey, D.J., Fitzgerald, J.F., McDougle, C.J., Gastrointestinal factors in autistic disorder: A critical review. Journal of Autism and Developmental Disorders 35:6 (2005), 713–727.
46. Estes, M.L., McAllister, A.K., Maternal immune activation: Implications for neuropsychiatric disorders. Science 353:6301 (2016), 772–777.
47. Evangeliou, A., Vlachonikolis, I., Mihailidou, H., Spilioti, M., Skarpalezou, A., Makaronas, N., Smeitink, J., Application of a ketogenic diet in children with autistic behavior: Pilot study. Journal of Child Neurology 18 (2003), 113–118.
48. Fankhauser, M.P., Karumanchi, V.C., German, M.L., Yates, A., Karumanchi, S.D., A double-blind placebo-controlled study of the efficacy of transdermal clonidine in autism. The Journal of Clinical Psychiatry 53:3 (1992), 77–82.
49. Filipek, P.A., Accardo, P.J., Baranek, G.T., Cook, E.H. Jr., Dawson, G., Gordon, B., Volkmar, F.R., The screening and diagnosis of autistic spectrum disorders. Journal of Autism and Developmental Disorders 29:6 (1999), 439–484.
50. Fishman, I., Keown, C.L., Lincoln, A.J., Pineda, J.A., Müller, R.A., Atypical cross talk between mentalizing and mirror neuron networks in autism spectrum disorder. JAMA Psychiatry 71:7 (2014), 751–760.
51. Gardener, H., Spiegelman, D., Buka, S.L., Prenatal risk factors for autism: Comprehensive meta-analysis. The British Journal of Psychiatry 195 (2009), 7–14.
52. Ghuman, J., Aman, M.G., Lecavalier, L., Riddle, M.A., Gelenberg, A., Wright, R., Fort, C., Randomized, placebo-controlled, crossover study of methylphenidate for attention-deficit/hyperactivity disorder symptoms in preschoolers with developmental disorders. Journal of Child and Adolescent Psychopharmacology 19 (2009), 329–339.
53. Gidaya, N.B., Lee, B.K., Burstyn, I., Yudell, M., Mortensen, E.L., Newschaffer, C.J., In utero exposure to selective serotonin reuptake inhibitors and risk for autism spectrum disorder. Journal of Autism and Developmental Disorders 44:10 (2014), 2558–2567.
54. Gillberg, C., Gillberg, C., Råstam, M., Wentz, E., The Asperger Syndrome (and high-functioning autism) Diagnostic Interview (ASDI): A preliminary study of a new structured clinical interview. Autism 5:1 (2001), 57–66.
55. Glidden, D., Bouman, W.P., Jones, B.A., Arcelus, J., Gender dysphoria and autism spectrum disorder: A systematic review of the literature. Sexual Medicine Reviews 4:1 (2016), 3–14.
56. Gottschall, E., Digestion-gut-autism connection: The specific carbohydrate diet. Medical Veritas 1 (2004), 261–271.
57. Green, L., Fein, D., Modahl, C., Feinstein, C., Waterhouse, L., Morris, M., Oxytocin and autistic disorder: Alterations in peptide forms. Biological Psychiatry 50 (2001), 609–613.
58. Greenspan, S.I., Wieder, S., Developmental patterns and outcomes in infants and children with disorders in relating and communicating: A chart review of 200 cases of children with autistic spectrum diagnoses. Journal of Developmental and Learning Disorders 1 (1997), 87–141.
59. Guastella, A.J., Einfeld, S.L., Gray, K.M., Rinehart, N.J., Tonge, B.J., Lambert, T.J., Hickie, I.B., Intranasal oxytocin improves emotion recognition for youth with autism spectrum disorders. Biological Psychiatry 67 (2010), 692–694.
60. Guastella, A.J., Gray, K.M., Rinehart, N.J., Alvares, G.A., Tonge, B.J., Hickie, I.B., Einfeld, S.L., The effects of a course of intranasal oxytocin on social behaviors in youth diagnosed with autism spectrum disorders: A randomized controlled trial. Journal of Child Psychology and Psychiatry 56 (2015), 444–452.
61. Halfon, N., Kuo, A.A., What DSM-5 could mean to children with autism and their families. JAMA Pediatrics 167:7 (2013), 608–613.
62. Hall, S.S., Lightbody, A.A., Reiss, A.L., Compulsive, self-injurious, and autistic behavior in children and adolescents with fragile X syndrome. American Journal of Mental Retardation 113:1 (2008), 44–53.
63. Hallmayer, J., Cleveland, S., Torres, A., Phillips, J., Cohen, B., Torigoe, T., Risch, N., Genetic heritability and shared environmental factors among twin pairs with autism. Archives of General Psychiatry 68:11 (2011), 1095–1102.
64. Halwani, G.F., Loui, P., Rüber, T., Schlaug, G., Effects of practice and experience on the arcuate fasciculus: Comparing singers, instrumentalists, and non-musicians. Frontiers in Psychology, 2, 2011, 156.
65. Handen, B.L., Johnson, C.R., Lubetsky, M., Efficacy of methylphenidate among children with autism and symptoms of attention-deficit hyperactivity disorder. Journal of Autism and Developmental Disorders 30 (2000), 245–255.
66. Handen, B.L., Sahl, R., Hardan, A.Y., Guanfacine in children with autism and/or intellectual disabilities. Journal of Developmental and Behavioral Pediatrics 29:4 (2008), 303–308.
67. Hanson, E., Kalish, L.A., Bunce, E., Curtis, C., McDaniel, S., Ware, J., Petry, J., Use of complementary and alternative medicine among children diagnosed with autism spectrum disorder. Journal of Autism and Developmental Disorders 37:4 (2007), 628–636.
68. Hardan, A.Y., Jou, R.J., Handen, B.L., Retrospective study of quetiapine in children and adolescents with pervasive developmental disorders. Journal of Autism and Developmental Disorders 35:3 (2005), 387–391.
69. Heaton, P., Assessing musical skills in autistic children who are not savants. Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences 364:1522 (2009), 1443–1447.
70. Hesselmark, E., Plenty, S., Bejerot, S., Group cognitive behavioural therapy and group recreational activity for adults with autism spectrum disorders: A preliminary randomized controlled trial. Autism 18 (2014), 672–683.
71. Hippler, K., Klicpera, C., A retrospective analysis of the clinical case records of ‘autistic psychopaths’ diagnosed by Hans Asperger and his team at the University Children's Hospital, Vienna. Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences 358:1430 (2003), 291–301.
72. Ho, B.P.V., Stephenson, J., Carter, M., Cognitive-behavioral approaches for children with autism spectrum disorder: A trend analysis. Research in Autism Spectrum Disorders 45 (2018), 27–41.
73. Hollander, E., Bartz, J., Chaplin, W., Phillips, A., Sumner, J., Soorya, L., Wasserman, S., Oxytocin increases retention of social cognition in autism. Biological Psychiatry 61 (2007), 498–503.
74. Hollander, E., Phillips, A., Chaplin, W., Zagursky, K., Novotny, S., Wasserman, S., Iyengar, R., A placebo controlled crossover trial of liquid fluoxetine on repetitive behaviors in childhood and adolescent autism. Neuropsychopharmacology 30:3 (2005), 582–589.
75. Hollander, E., Wasserman, S., Swanson, E.N., Chaplin, W., Schapiro, M.L., Zagursky, K., Novotny, S., A double-blind placebo-controlled pilot study of olanzapine in childhood/adolescent pervasive developmental disorder. Journal of Child and Adolescent Psychopharmacology 16:5 (2006), 541–548.
76. Horvath, A., Lukasik, J., Szajewska, H., ω-3 fatty acid supplementation does not affect autism spectrum disorder in children: A systematic review and meta-analysis. The Journal of Nutrition 147 (2017), 367–376.
77. Huerta, M., Bishop, S.L., Duncan, A., Hus, V., Lord, C., Application of DSM-5 criteria for autism spectrum disorder to three samples of children with DSM-IV diagnoses of pervasive developmental disorders. The American Journal of Psychiatry 169 (2012), 1056–1064.
78. Hviid, A., Melbye, M., Pasternak, B., Use of selective serotonin reuptake inhibitors during pregnancy and risk of autism. The New England Journal of Medicine 369:25 (2013), 2406–2415.
79. Ingersoll, B., Schreibman, L., Teaching reciprocal imitation skills to young children with autism using a naturalistic behavioral approach: Effects on language, pretend play, and joint attention. Journal of Autism and Developmental Disorders 36 (2006), 487–505.
80. Jaselskis, C.A., Cook, E.H. Jr., Fletcher, K.E., Leventhal, B.L., Clonidine treatment of hyperactive and impulsive children with autistic disorder. Journal of Clinical Psychopharmacology 12:5 (1992), 322–327.
81. Jokiranta, E., Brown, A.S., Heinimaa, M., Cheslack-Postava, K., Suominen, A., Sourander, A., Parental psychiatric disorders and autism spectrum disorders. Psychiatry Research 207:3 (2013), 203–211.
82. Joshi, G., Biederman, J., Petty, C., Goldin, R.L., Furtak, S.L., Wozniak, J., Examining the comorbidity of bipolar disorder and autism spectrum disorders: A large controlled analysis of phenotypic and familial correlates in a referred population of youth with bipolar I disorder with and without autism spectrum disorders. The Journal of Clinical Psychiatry 74 (2013), 578–586.
83. Kallman, F.J., Roth, B., Genetic aspects of preadolescent schizophrenia. The American Journal of Psychiatry 112 (1956), 599–606.
84. Kana, R.K., Keller, T.A., Cherkassky, V.L., Minshew, N.J., Just, M.A., Atypical frontal-posterior synchronization of theory of mind regions in autism during mental state attribution. Social Neuroscience 4:2 (2009), 135–152.
85. Kanner, L., Autistic disturbances of affective contact. The Nervous Child 2 (1943), 217–250.
86. Kawicka, A., Regulska-Ilow, B., How nutritional status, diet and dietary supplements can affect autism. A review. Roczniki Państwowego Zakładu Higieny 64 (2013), 1–12.
87. Kerns, C.M., Roux, A.M., Connell, J.E., Shattuck, P.T., Adapting cognitive behavioral techniques to address anxiety and depression in cognitively able emerging adults on the autism spectrum. Cognitive and Behavioral Practice 23 (2016), 329–340.
88. King, B.H., Hollander, E., Sikich, L., McCracken, J.T., Scahill, L., Bregman, J.D., STAART Psychopharmacology Network, Lack of efficacy of citalopram in children with autism spectrum disorders and high levels of repetitive behavior: Citalopram ineffective in children with autism. Archives of General Psychiatry 66:6 (2009), 583–590.
89. Klin, A., Saulnier, C.A., Sparrow, S.S., Cicchetti, D.V., Volkmar, F.R., Lord, C., Social and communication abilities and disabilities in higher functioning individuals with autism spectrum disorders: The Vineland and the ADOS. Journal of Autism and Developmental Disorders 37 (2007), 748–759.
90. Koegel, L.K., Park, M.N., Koegel, R.L., Using self-management to improve the reciprocal social conversation of children with autism spectrum disorder. Journal of Autism and Developmental Disorders 44 (2014), 1055–1063.
91. Koelsch, S., A neuroscientific perspective on music therapy. Annals of the New York Academy of Sciences 1169 (2009), 374–384.
92. Kolvin, I., Studies in the childhood psychosis. I. Diagnostic criteria and classification. The British Journal of Psychiatry 118 (1971), 381–384.
93. Kreslins, A., Robertson, A.E., Melville, C., The effectiveness of psychosocial interventions for anxiety in children and adolescents with autism spectrum disorder: A systematic review and meta-analysis. Child and Adolescent Psychiatry and Mental Health, 9, 2015, 22.
94. Kulage, K.M., Smaldone, A.M., Cohn, E.G., How will DSM-5 affect autism diagnosis? A systematic literature review and meta-analysis. Journal of Autism and Developmental Disorders 44 (2014), 1918–1932.
95. Lacivita, E., Perrone, R., Margari, L., Leopoldo, M., Targets for drug therapy for autism spectrum disorder: Challenges and future directions. Journal of Medicinal Chemistry 60 (2017), 9114–9141.
96. Lai, M.-C., Lombardo, M.V., Baron-Cohen, S., Autism. Lancet 383 (2014), 896–910.
97. Landgraf, R., Neumann, I.D., Vasopressin and oxytocin release within the brain: A dynamic concept of multiple and variable modes of neuropeptide communication. Frontiers in Neuroendocrinology 25 (2004), 150–176.
98. Landrigan, P.J., What causes autism? Exploring the environmental contribution. Current Opinion in Pediatrics 22 (2010), 219–225.
99. Langworthy-Lam, K.S., Aman, M.G., van Bourgondien, M.E., Prevalence and patterns of use of psychoactive medicines in individuals with autism in the Autism Society of North Carolina. Journal of Child and Adolescent Psychopharmacology 12 (2002), 311–321.
100. Leitner, Y., The co-occurrence of autism and attention deficit hyperactivity disorder in children - What do we know?. Frontiers in Human Neuroscience, 8, 2014, 268.
101. Leng, G., Ludwig, M., Intranasal oxytocin: Myths and delusions. Biological Psychiatry 79 (2016), 243–250.
102. Leyfer, O.T., Folstein, S.E., Bacalman, S., Davis, N.O., Dinh, E., Morgan, J., Lainhart, J.E., Comorbid psychiatric disorders in children with autism: Interview development and rates of disorders. Journal of Autism and Developmental Disorders 36:7 (2006), 849–861.
103. Liddle, K., Implementing the picture exchange communication system (PECS). International Journal of Language & Communication Disorders(36 Suppl), 2001, 391–395.
104. LoParo, D., Waldman, I.D., The oxytocin receptor gene (OXTR) is associated with autism spectrum disorder: A meta-analysis. Molecular Psychiatry 20 (2015), 640–646.
105. Lord, C., Rutter, M., Le Couteur, A., Autism diagnostic interview-revised: A revised version of a diagnostic interview for caregivers of individuals with possible pervasive developmental disorders. Journal of Autism and Developmental Disorders 24:5 (1994), 659–685.
106. Luby, J., Mrakotsky, C., Stalets, M.M., Belden, A., Heffelfinger, A., Williams, M., Spitznagel, E., Risperidone in preschool children with autistic spectrum disorders: An investigation of safety and efficacy. Journal of Child and Adolescent Psychopharmacology 16:5 (2006), 575–587.
107. Lugnegard, T., Hallerbäck, M.U., Gillberg, C., Psychiatric comorbidity in young adults with a clinical diagnosis of Asperger syndrome. Research in Developmental Disabilities 32 (2011), 1910–1917.
108. Mahjouri, S., Lord, C.E., What the DSM-5 portends for research, diagnosis, and treatment of autism spectrum disorders. Current Psychiatry Reports 14 (2012), 739–747.
109. Mahoney, G., Perales, F., Relationship-focused early intervention with children with pervasive developmental disorders and other disabilities: A comparative study. Journal of Developmental and Behavioral Pediatrics 26 (2005), 77–85.
110. Maljaars, J., Noens, I., Scholte, E., van Berckelaer-Onnes, I., Evaluation of the criterion and convergent validity of the diagnostic interview for social and communication disorders in young and low-functioning children. Autism 16:5 (2012), 487–497.
111. Malone, R.P., Cater, J., Sheikh, R.M., Choudhury, M.S., Delaney, M.A., Olanzapine versus haloperidol in children with autistic disorder: An open pilot study. Journal of the American Academy of Child and Adolescent Psychiatry 40 (2001), 887–894.
112. Marcus, R.N., Owen, R., Kamen, L., Manos, G., McQuade, R.D., Carson, W.H., Aman, M.G., A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder. Journal of the American Academy of Child and Adolescent Psychiatry 48:11 (2009), 1110–1119.
113. Martin, A., Koenig, K., Anderson, G., Scahill, L., Lowdose fluvoxamine treatment of children and adolescents with pervasive developmental disorders: A prospective, open-label study. Journal of Autism and Developmental Disorders 33 (2003), 77–85.
114. Martin, A., Koenig, K., Scahill, L., Bregman, J., Open-label quetiapine in the treatment of children and adolescents with autistic disorder. Journal of Child and Adolescent Psychopharmacology 9 (1999), 99–107.
115. Matson, J.L., Wilkins, J., Boisjoli, J.A., Smith, K.R., The validity of the autism spectrum disorders-diagnosis for intellectually disabled adults (ASD-DA). Research in Developmental Disabilities 29:6 (2008), 537–546.
116. Mayes, S.D., Calhoun, S.L., Murray, M.J., Ahuja, M., Smith, L.A., Anxiety, depression, and irritability in children with autism relative to other neuropsychiatry disorders and typical development. Research in Autism Spectrum Disorders 5 (2011), 474–485.
117. Mazahery, H., Stonehouse, W., Delshad, M., Kruger, M.C., Conlon, C.A., Beck, K.L., von Hurst, P.R., Relationship between long chain n-3 polyunsaturated fatty acids and autism spectrum disorder: Systematic review and meta-analysis of case-control and randomised controlled trials. Nutrients, 2018 (in press).
118. McCracken, J.T., McGough, J., Shah, B., Cronin, P., Hong, D., Aman, M.G., Research Units on Pediatric Psychopharmacology Autism Network, Risperidone in children with autism and serious behavioral problems. The New England Journal of Medicine 347:5 (2002), 314–321.
119. McDougle, C.J., Brodkin, E.S., Naylor, S.T., Carlson, D.C., Cohen, D.J., Price, L.H., Sertraline in adults with pervasive developmental disorders: A prospective, open-label investigation. Journal of Clinical Psychopharmacology 18 (1998), 62–66.
120. McDougle, C.J., Holmes, J.P., Carlson, D.C., Pelton, G.H., Cohen, D.J., Price, L.H., A double-blind, placebo-controlled study of risperidone in adults with autistic disorder and other pervasive developmental disorders. Archives of General Psychiatry 55:7 (1998), 633–641.
121. McDougle, C.J., Kem, D.L., Posey, D.J., Case series: Use of ziprasidone for maladaptive symptoms in youths with autism. Journal of the American Academy of Child and Adolescent Psychiatry 41 (2002), 921–927.
122. McDougle, C.J., Naylor, S.T., Cohen, D.J., Volkmar, F.R., Heninger, G.R., Price, L.H., A double-blind, placebo-controlled study of fluvoxamine in adults with autistic disorder. Archives of General Psychiatry 53 (1996), 1001–1008.
123. Meiri, G., Bichovsky, Y., Belmaker, R.H., Omega 3 fatty acid treatment in autism. Journal of Child and Adolescent Psychopharmacology 19 (2009), 449–451.
124. Mesibov, G.B., Schopler, E., Schaffer, B., Michal, N., Use of the childhood autism rating scale with autistic adolescents and adults. Journal of the American Academy of Child and Adolescent Psychiatry 28:4 (1989), 538–541.
125. Ming, X., Gordon, E., Kang, N., Wagner, G.C., Use of clonidine in children with autism spectrum disorders. Brain and Development 30 (2008), 454–460.
126. Modahl, C., Green, L., Fein, D., Morris, M., Waterhouse, L., Feinstein, C., Levin, H., Plasma oxytocin levels in autistic children. Biological Psychiatry 43 (1998), 270–277.
127. Montes, G., Halterman, J.S., Characteristics of school-age children with autism. Journal of Developmental and Behavioral Pediatrics 26:5 (2006), 375–385.
128. Munesue, T., Ono, Y., Mutoh, K., Shimoda, K., Nakatani, H., Kikuchi, M., High prevalence of bipolar disorder comorbidity in adolescents and young adults with high-functioning autism spectrum disorder: A preliminary study of 44 outpatients. Journal of Affective Disorders 111:2–3 (2008), 170–175.
129. Muris, P., Steerneman, P., Merckelbach, H., Holdrinet, I., Meesters, C., Comorbid anxiety symptoms in children with pervasive developmental disorders. Journal of Anxiety Disorders 12 (1998), 387–393.
130. Nadeau, J., Sulkowski, M.L., Ung, D., Wood, J.J., Lewin, A.B., Murphy, T.K., Storch, E.A., Treatment of comorbid anxiety and autism spectrum disorders. Neuropsychiatry 1:6 (2011), 567–578.
131. Namerow, L., Thomas, P., Bostic, J.Q., Prince, J., Monuteaux, M.C., Use of citalopram in pervasive developmental disorders. Journal of Developmental and Behavioral Pediatrics 24 (2003), 104–108.
132. Neal, D., Matson, J.L., Hattier, M.A., A comparison of diagnostic criteria on the Autism Spectrum Disorder Observation for Children (ASD-OC). Developmental Neurorehabilitation 15:5 (2012), 329–335.
133. Neal, D., Matson, J.L., Hattier, M.A., Validity of the Autism Spectrum Disorder Observation for Children (ASD-OC). Journal of Mental Health Research in Intellectual Disabilities 7:1 (2014), 14–33.
134. Newcorn, J.H., Schulz, K., Harrison, M., DeBellis, M.D., Udarbe, J.K., Halperin, J.M., Alpha 2 adrenergic agonists. Neurochemistry, efficacy, and clinical guidelines for use in children. Pediatric Clinics of North America, 45(5), 1998 (1099-1022).
135. Ooi, Y.P., Weng, S.J., Jang, L.Y., Low, L., Seah, J., Teo, S., Sung, M., Omega-3 fatty acids in the management of autism spectrum disorders: Findings from an open-label pilot study in Singapore. European Journal of Clinical Nutrition 69 (2015), 969–971.
136. Owen, R., Sikich, L., Marcus, R.N., Corey-Lisle, P., Manos, G., McQuade, R.D., Findling, R.L., Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder. Pediatrics 124:6 (2009), 1533–1540.
137. Owley, T., Walton, L., Salt, J., Guter, S.J. Jr., Winnega, M., Leventhal, B.L., Cook, E.H. Jr., An open-label trial of escitalopram in pervasive developmental disorders. Journal of the American Academy of Child and Adolescent Psychiatry 44 (2005), 343–348.
138. Pardo, C.A., Vargas, D.L., Zimmerman, A.W., Immunity, neuroglia and neuroinflammation in autism. International Review of Psychiatry 17:6 (2005), 485–495.
139. Patterson, P.H., Immune involvement in schizophrenia and autism: Etiology, pathology and animal models. Behavioural Brain Research 204:2 (2009), 313–321.
140. Pendyala, G., Chou, S., Jung, Y., Coiro, P., Spartz, E., Padmashri, R., Dunaevsky, A., Materanl immune activation causes behavioral impairments and altered cerebellar cytokine and synaptic protein expression. Neuropsychopharmacology 42:7 (2017), 1435–1446.
141. Posey, D.J., Stigler, K.A., Erickson, C.A., McDougle, C.J., Antipsycohtics in the treatment of autism. The Journal of Clinical Investigation 118:1 (2008), 6–14.
142. Posey, D.J., Walsh, K.H., Wilson, G., McDougle, C.J., Risperidone in the treatment of two very young children with autism. Journal of Child and Adolescent Psychopharmacology 9 (1999), 273–276.
143. Potenza, M.N., Holmes, J.P., Kanes, S.J., McDougle, C.J., Olanzapine treatment of children, adolescents, and adults with pervasive developmental disorders: An open-label pilot study. Journal of Clinical Psychopharmacology 19 (1999), 37–44.
144. Quintana, H., Birmaher, B., Stedge, D., Lennon, S., Freed, J., Bridge, J., Greenhill, L., Use of methylphenidate in the treatment of children with autistic disorder. Journal of Autism and Developmental Disorders 25 (1995), 283–294.
145. Rao, P.A., Landa, R.J., Association between severity of behavioral phenotype and comorbid attention deficit hyperactivity disorder symptoms in children with autism spectrum disorders. Autism 18:3 (2014), 272–280.
146. Rapoport, J., Chavez, A., Greenstein, D., Addington, A., Gogtay, N., Autism spectrum disorders and childhood-onset schizophrenia: Clinical and biological contributions to a relation revisited. Journal of the American Academy of Child and Adolescent Psychiatry 48:1 (2009), 10–18.
147. Ratni, H., Rogers-Evans, M., Bissantz, C., Grundschober, C., Moreau, J.L., Schuler, F., Schnider, P., Discovery of highly selective brain-penetrant vasopressin 1a antagonists for the potential treatment of autism via a chemogenomic and scaffold hopping approach. Journal of Medicinal Chemistry 58 (2015), 2275–2289.
148. Rauh, V.A., Garfinkel, R., Perera, F.P., Andrews, H.F., Hoepner, L., Barr, D.B., Whyatt, R.W., Impact of prenatal chlorpyrifos exposure on neurodevelopment in the first 3 years of life among inner-city children. Pediatrics 118:6 (2006), e1845–1859.
149. Reichow, B., Barton, E.E., Boyd, B.A., Hume, K., Early intensive behavioral intervention (EIBI) for young children with autism spectrum disorders (ASD). Cochrane Database of Systematic Reviews, 10, 2012, CD009260.
150. Research Units on Pediatric Psychopharmacology (RUPP) Autism Network, Randomized, controlled, crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity. Archives of General Psychiatry 62 (2005), 1266–1274.
151. Roche Press Release, FDA grants Breakthrough Therapy Designation for Roche's balovaptan in autism spectrum disorder. https://www.roche.com/investors/updates/inv-update-2018-01-29.htm, 2018, January 29.
152. Rosenberg, R.E., Kaufmann, W.E., Law, J.K., Law, P.A., Parent report of community psychiatric comorbid diagnoses in autism spectrum disorders. Autism Research and Treatment 2011 (2011), 405–849.
153. Rosenberg, R.E., Law, J.K., Yenokyan, G., McGready, J., Kaufmann, W.E., Law, P.A., Characteristics and concordance of autism spectrum disorders among 277 twin pairs. Archives of Pediatrics & Adolescent Medicine 163:10 (2009), 907–914.
154. Russell, A.J., Mataix-Cols, D., Anson, M., Murphy, D.G., Obsessions and compulsions in Asperger syndrome and high-functioning autism. The British Journal of Psychiatry 186 (2005), 525–528.
155. Russell, A.T., Bott, L., Sammons, C., The phenomenology of schizophrenia occurring in childhood. Journal of the American Academy of Child and Adolescent Psychiatry 28 (1989), 399–407.
156. Sallows, G.O., Graupner, T.D., Intensive behavioral treatment for children with autism: Four-year outcome and predictors. American Journal of Mental Retardation 110 (2005), 417–438.
157. Sathe, N., Andrews, J.C., McPheeters, M.L., Warren, Z.E., Nutritional and dietary interventions for autism spectrum disorder: A systematic review. Pediatrics, 2018 (in press).
158. Scahill, L., Boorin, S.G., Psychopharmacology in children with PDD: Review of current evidence. Reichow, B., Doehring, P., Cicchetti, D.V., Volkmar, F.R., (eds.) Evidence-based practices and treatments for children with autism, 2011, Springer, NY, USA, 231–243.
159. Scahill, L., McCracken, J.T., King, B.H., Rockhill, C., Shah, B., Politte, L., Research Units on Pediatric Psychopharmacology Autism Network, Extended-eelease guanfacine for hyperactivity in children with autism spectrum disorder. The American Journal of Psychiatry 172:12 (2015), 1197–1206.
160. Schendel, D., Bhasin, T.K., Birth weight and gestational age characteristics of children with autism, including a comparison with other developmental disabilities. Pediatrics 121:6 (2008, Jun), 1155–1164.
161. Schlaug, G., Marchina, S., Norton, A., Evidence for plasticity in white matter tracts of chronic aphasic patients undergoing intense intonation-based speech therapy. Annals of the New York Academy of Sciences 1169 (2009), 385–394.
162. Schopler, E., Reichler, R.J., DeVellis, R.F., Daly, K., Toward objective classification of childhood autism: Childhood autism rating scale (CARS). Journal of Autism and Developmental Disorders 10:1 (1980), 91–103.
163. Sharda, M., Midha, R., Malik, S., Mukerji, S., Singh, N.C., Fronto-temporal connectivity is preserved during sung but not spoken word listening, across the autism spectrum. Autism Research 8:2 (2015), 174–186.
164. Shea, S., Turgay, A., Carroll, A., Schulz, M., Orlik, H., Smith, I., Dunbar, F., Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders. Pediatrics 114:5 (2004), e634–641.
165. Sikora, D.M., Vora, P., Coury, D.L., Rosenberg, D., Attention-deficit/hyperactivity disorder symptoms, adaptive functioning, and quality of life in children with autism spectrum disorder. Pediatrics 130:Suppl. 2 (2012), S91–S97.
166. Simonoff, E., Pickles, A., Charman, T., Chandler, S., Loucas, T., Baird, G., Psychiatric disorders in children with autism spectrum disorders: Prevalence, comorbidity, and associated factors in a population-derived sample. Journal of the American Academy of Child and Adolescent Psychiatry 47 (2008), 921–929.
167. Skokauskas, N., Frodl, T., Overlap between autism spectrum disorder and bipolar affective disorder. Psychopathology 48 (2015), 209–216.
168. Skuse, D., Warrington, R., Bishop, D., Chowdhury, U., Lau, J., Mandy, W., Place, M., The developmental, dimensional and diagnostic interview (3di): A novel computerized assessment for autism spectrum disorders. Journal of the American Academy of Child and Adolescent Psychiatry 43:5 (2004), 548–558.
169. Smalley, S.L., Autism and tuberous sclerosis. Journal of Autism and Developmental Disorders 28 (1998), 407–414.
170. Sørensen, M.J., Grønborg, T.K., Christensen, J., Parner, E.T., Vestergaard, M., Schendel, D., Pedersen, L.H., Antidepressant exposure in pregnancy and risk of autism spectrum disorders. Clinical Epidemiology 5 (2013), 449–459.
171. Spain, D., Blainey, S.H., Group social skills interventions for adults with high-functioning autism spectrum disorders: A systematic review. Autism 19 (2015), 874–886.
172. van Steensel, F.J., Bögels, S.M., Perrin, S., Anxiety disorders in children and adolescents with autistic spectrum disorders: A meta-analysis. Clinical Child and Family Psychology Review 14:3 (2011), 302–317.
173. Steingard, R.J., Zimnitzky, B., DeMaso, D.R., Bauman, M.L., Bucci, J.P., Sertraline treatment of transition-associated anxiety and agitation in children with autistic disorder. Journal of Child and Adolescent Psychopharmacology 7 (1997), 9–15.
174. Sukhodolsky, D.G., Bloch, M.H., Panza, K.E., Reichow, B., Cognitive-behavioral therapy for anxiety in children with high-functioning autism: A meta-analysis. Pediatrics 132 (2013), e1341–e1350.
175. Tsai, L.Y., Sensitivity and specificity: DSM-IV versus DSM-5 criteria for autism spectrum disorder. The American Journal of Psychiatry 169:10 (2012), 1009–1011.
176. Tschoner, A., Engl, J., Laimer, M., Kaser, S., Rettenbacher, M., Fleischhacker, W.W., Ebenbichler, C.F., Metabolic side effects of antipsychotic medication. International Journal of Clinical Practice 61:8 (2007), 1356–1370.
177. Umbricht, D., Del Valle, R.M., Hollander, E., McCracken, J.T., Shic, F., Scahill, L., Fontoura, P., A single dose, randomized, controlled proof-of-mechanism study of a novel vasopressin 1a receptor antagonist (RG7713) in high-functioning adults with autism spectrum disorder. Neuropsychopharmacology 42:9 (2017), 1914–1923.
178. Ung, D., Selles, R., Small, B.J., Storch, E.A., A systematic review and meta-analysis of cognitive-behavioral therapy for anxiety in youth with high-functioning autism spectrum disorders. Child Psychiatry and Human Development 46 (2015), 533–547.
179. Vannucchi, G., Masi, G., Toni, C., Dell'Osso, L., Erfurth, A., Perugi, G., Bipolar disorder in adults with Asperger's syndrome: A systematic review. Journal of Affective Disorders 168 (2014), 151–160.
180. Vismara, L.A., Rogers, S.J., Behavioral treatments in autism spectrum disorder: What do we know?. Annual Review of Clinical Psychology 6 (2010), 447–468.
181. Vllasaliu, L., Jensen, K., Hoss, S., Landenberger, M., Menze, M., Schütz, M., Freitag, C.M., Diagnostic instruments for autism spectrum disorder (ASD). The Cochrane Database of Systematic Reviews, 2016, January 12.
182. Watanabe, T., Kuroda, M., Kuwabara, H., Aoki, Y., Iwashiro, N., Tatsunobu, N., Yamasue, H., Clinical and neural effects of six-week administration of oxytocin on core symptoms of autism. Brain 138 (2015), 3400–3412.
183. Watkins, J.M., Asarnow, R.F., Tanguay, P.E., Symptom development in childhood onset schizophrenia. Journal of Child Psychology and Psychiatry 29:6 (1988), 865–878.
184. Weston, L., Hodgekins, J., Langdon, P.E., Effectiveness of cognitive behavioural therapy with people who have autistic spectrum disorders: A systematic review and meta-analysis. Clinical Psychology Review 49 (2016), 41–54.
185. White, S.W., Ollendick, T., Scahill, L., Oswald, D., Albano, A.M., Preliminary efficacy of a cognitive-behavioral treatment program for anxious youth with autism spectrum disorders. Journal of Autism and Developmental Disorders 39 (2009), 1652–1662.
186. White, S.W., Oswald, D., Ollendick, T., Scahill, L., Anxiety in children and adolescents with autism spectrum disorders. Clinical Psychology Review 29 (2009), 216–229.
187. Whiteley, P., Haracopos, D., Knivsberg, A.M., Reichelt, K.L., Parlar, S., Jacobsen, J., Shattock, P., The ScanBrit randomised, controlled, single-blind study of a gluten- and casein-free dietary intervention for children with autism spectrum disorders. Nutritional Neuroscience 13 (2010), 87–100.
188. Wieland, L.S., Manheimer, E., Berman, B.M., Development and classification of an operational definition of complementary and alternative medicine for the Cochrane Collaboration. Alternative Therapies in Health and Medicine 17:2 (2011), 50–59.
189. Williams, K., Wheeler, D.M., Silove, N., Selective serotonin reuptake inhibitors for autism spectrum disorders. Cochrane Database of Systematic Reviews, 8, 2010, CD004677.
190. Wing, L., Leekam, S.R., Libby, S.J., Gould, J., Larcombe, M., The diagnostic interview for social and communication disorders: Background, inter-rater reliability and clinical use. Journal of Child Psychology and Psychiatry 43 (2002), 307–325.
191. Yatawara, C.J., Einfeld, S.L., Hickie, I.B., Davenport, T.A., Guastella, A.J., The effect of oxytocin nasal spray on social interaction deficits observed in young children with autism: A randomized clinical crossover trial. Molecular Psychiatry 21 (2016), 1225–1231.
192. Zablotsky, B., Black, L.I., Blumberg, S.J., Estimated prevalence of children with diagnosed developmental disabilities in the United States, 2014–2016. NCHS Data Brief, no 291. 2017, National Center for Health Statistics, Hyattsville, MD.
193. Zafeiriou, D.I., Ververi, A., Vargiami, E., Childhood autism and associated comorbidities. Brain & Development 29:5 (2007), 257–272.